Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aimiduoer hydrochloride is a novel small molecule antiviral agent developed for the treatment of chronic hepatitis B virus (HBV) infection. Originally designed by researchers at Shenyang Pharmaceutical University, it is a structural derivative of the broad-spectrum antiviral drug umifenovir (Arbidol). Aimiduoer functions as an HBV capsid assembly modulator (CAM), specifically targeting the HBV core protein (HBcAg). By binding to the core protein, it interferes with the proper assembly of the viral nucleocapsid, which is essential for the encapsidation of pregenomic RNA and subsequent viral DNA synthesis. This disruption effectively inhibits the replication of HBV and the production of infectious virions. The drug has been advanced into clinical trials in China in collaboration with Guangzhou Boji Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aimiduoer hydrochloride.